Pancreatic cancer cells resistance to gemcitabine: The role of MUC4 mucin

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Background: A major obstacle to the successful management of pancreatic cancer is to acquire resistance to the existing chemotherapeutic agents. Resistance to gemcitabine, the standard first-line chemotherapeutic agent for advanced and metastatic pancreatic cancer, is mainly attributed to an altered apoptotic threshold in the pancreatic cancer. The MUC4 transmembrane glycoprotein is aberrantly overexpressed in the pancreatic cancer and recently, has been shown to increase pancreatic tumour cell growth by the inhibition of apoptosis. Methods: Effect of MUC4 on pancreatic cancer cells resistance to gemcitabine was studied in MUC4-expressing and MUC4-knocked down pancreatic cancer cell lines after treatment with gemcitabine by Annexin-V staining, DNA fragmentation assay, assessment of mitochondrial cytochrome c release, immunoblotting and co-immunoprecipitation techniques. Results: Annexin-V staining and DNA fragmentation experiment demonstrated that MUC4 protects CD18/HPAF pancreatic cancer cells from gemcitabine-induced apoptosis. In concert with these results, MUC4 also attenuated mitochondrial cytochrome c release and the activation of caspase-9. Further, our results showed that MUC4 exerts anti-apoptotic function through HER2/extracellular signal-regulated kinase-dependent phosphorylation and inactivation of the pro-apoptotic protein Bad. Conclusion: Our results elucidate the function of MUC4 in imparting resistance to pancreatic cancer cells against gemcitabine through the activation of anti-apoptotic pathways and, thereby, promoting cell survival.

Original languageEnglish (US)
Pages (from-to)1155-1161
Number of pages7
JournalBritish journal of cancer
Volume101
Issue number7
DOIs
StatePublished - Sep 9 2009

Fingerprint

gemcitabine
Mucins
Pancreatic Neoplasms
Annexin A5
DNA Fragmentation
Cytochromes c
Apoptosis
Staining and Labeling
Apoptosis Regulatory Proteins
Caspase 9
Extracellular Signal-Regulated MAP Kinases
Immunoprecipitation
Immunoblotting
Cell Survival
Glycoproteins

Keywords

  • Chemotherapy
  • MUC4
  • Pancreatic cancer
  • Resistance

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pancreatic cancer cells resistance to gemcitabine : The role of MUC4 mucin. / Bafna, S.; Kaur, Sukwinder; Momi, N.; Batra, Surinder Kumar.

In: British journal of cancer, Vol. 101, No. 7, 09.09.2009, p. 1155-1161.

Research output: Contribution to journalArticle

@article{f7efbe8dca8840a9bc9f508ee8c68200,
title = "Pancreatic cancer cells resistance to gemcitabine: The role of MUC4 mucin",
abstract = "Background: A major obstacle to the successful management of pancreatic cancer is to acquire resistance to the existing chemotherapeutic agents. Resistance to gemcitabine, the standard first-line chemotherapeutic agent for advanced and metastatic pancreatic cancer, is mainly attributed to an altered apoptotic threshold in the pancreatic cancer. The MUC4 transmembrane glycoprotein is aberrantly overexpressed in the pancreatic cancer and recently, has been shown to increase pancreatic tumour cell growth by the inhibition of apoptosis. Methods: Effect of MUC4 on pancreatic cancer cells resistance to gemcitabine was studied in MUC4-expressing and MUC4-knocked down pancreatic cancer cell lines after treatment with gemcitabine by Annexin-V staining, DNA fragmentation assay, assessment of mitochondrial cytochrome c release, immunoblotting and co-immunoprecipitation techniques. Results: Annexin-V staining and DNA fragmentation experiment demonstrated that MUC4 protects CD18/HPAF pancreatic cancer cells from gemcitabine-induced apoptosis. In concert with these results, MUC4 also attenuated mitochondrial cytochrome c release and the activation of caspase-9. Further, our results showed that MUC4 exerts anti-apoptotic function through HER2/extracellular signal-regulated kinase-dependent phosphorylation and inactivation of the pro-apoptotic protein Bad. Conclusion: Our results elucidate the function of MUC4 in imparting resistance to pancreatic cancer cells against gemcitabine through the activation of anti-apoptotic pathways and, thereby, promoting cell survival.",
keywords = "Chemotherapy, MUC4, Pancreatic cancer, Resistance",
author = "S. Bafna and Sukwinder Kaur and N. Momi and Batra, {Surinder Kumar}",
year = "2009",
month = "9",
day = "9",
doi = "10.1038/sj.bjc.6605285",
language = "English (US)",
volume = "101",
pages = "1155--1161",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Pancreatic cancer cells resistance to gemcitabine

T2 - The role of MUC4 mucin

AU - Bafna, S.

AU - Kaur, Sukwinder

AU - Momi, N.

AU - Batra, Surinder Kumar

PY - 2009/9/9

Y1 - 2009/9/9

N2 - Background: A major obstacle to the successful management of pancreatic cancer is to acquire resistance to the existing chemotherapeutic agents. Resistance to gemcitabine, the standard first-line chemotherapeutic agent for advanced and metastatic pancreatic cancer, is mainly attributed to an altered apoptotic threshold in the pancreatic cancer. The MUC4 transmembrane glycoprotein is aberrantly overexpressed in the pancreatic cancer and recently, has been shown to increase pancreatic tumour cell growth by the inhibition of apoptosis. Methods: Effect of MUC4 on pancreatic cancer cells resistance to gemcitabine was studied in MUC4-expressing and MUC4-knocked down pancreatic cancer cell lines after treatment with gemcitabine by Annexin-V staining, DNA fragmentation assay, assessment of mitochondrial cytochrome c release, immunoblotting and co-immunoprecipitation techniques. Results: Annexin-V staining and DNA fragmentation experiment demonstrated that MUC4 protects CD18/HPAF pancreatic cancer cells from gemcitabine-induced apoptosis. In concert with these results, MUC4 also attenuated mitochondrial cytochrome c release and the activation of caspase-9. Further, our results showed that MUC4 exerts anti-apoptotic function through HER2/extracellular signal-regulated kinase-dependent phosphorylation and inactivation of the pro-apoptotic protein Bad. Conclusion: Our results elucidate the function of MUC4 in imparting resistance to pancreatic cancer cells against gemcitabine through the activation of anti-apoptotic pathways and, thereby, promoting cell survival.

AB - Background: A major obstacle to the successful management of pancreatic cancer is to acquire resistance to the existing chemotherapeutic agents. Resistance to gemcitabine, the standard first-line chemotherapeutic agent for advanced and metastatic pancreatic cancer, is mainly attributed to an altered apoptotic threshold in the pancreatic cancer. The MUC4 transmembrane glycoprotein is aberrantly overexpressed in the pancreatic cancer and recently, has been shown to increase pancreatic tumour cell growth by the inhibition of apoptosis. Methods: Effect of MUC4 on pancreatic cancer cells resistance to gemcitabine was studied in MUC4-expressing and MUC4-knocked down pancreatic cancer cell lines after treatment with gemcitabine by Annexin-V staining, DNA fragmentation assay, assessment of mitochondrial cytochrome c release, immunoblotting and co-immunoprecipitation techniques. Results: Annexin-V staining and DNA fragmentation experiment demonstrated that MUC4 protects CD18/HPAF pancreatic cancer cells from gemcitabine-induced apoptosis. In concert with these results, MUC4 also attenuated mitochondrial cytochrome c release and the activation of caspase-9. Further, our results showed that MUC4 exerts anti-apoptotic function through HER2/extracellular signal-regulated kinase-dependent phosphorylation and inactivation of the pro-apoptotic protein Bad. Conclusion: Our results elucidate the function of MUC4 in imparting resistance to pancreatic cancer cells against gemcitabine through the activation of anti-apoptotic pathways and, thereby, promoting cell survival.

KW - Chemotherapy

KW - MUC4

KW - Pancreatic cancer

KW - Resistance

UR - http://www.scopus.com/inward/record.url?scp=70349653064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349653064&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605285

DO - 10.1038/sj.bjc.6605285

M3 - Article

C2 - 19738614

AN - SCOPUS:70349653064

VL - 101

SP - 1155

EP - 1161

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -